Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 4th edition, 372 pages + the daily Top 10

Breast Cancer

Free Subscription Articles published in Lancet Oncol Retrieve available abstracts of 139 articles: HTML format

Single Articles

July 2020
1. MALEKPOUR M, Widger J
   Radiation-induced angiosarcoma in a patient with breast cancer.
   Lancet Oncol. 2020;21:e369.
   PubMed    
   
   
   May 2020
2. JONES RH, Casbard A, Carucci M, Foxley A, et al
   Fulvestrant plus capivasertib for metastatic breast cancer - Authors' reply.
   Lancet Oncol. 2020;21:e234.
   PubMed    
   
   
   
3. LUDMIR EB, McCaw ZR, Kim DH, Tian L, et al
   Fulvestrant plus capivasertib for metastatic breast cancer.
   Lancet Oncol. 2020;21:e233.
   PubMed    
   
   
   
4. DEKKER TJA
   Fulvestrant plus capivasertib for metastatic breast cancer.
   Lancet Oncol. 2020;21:e232.
   PubMed    
   
   
   
5. BENSON JR
   Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ.
   Lancet Oncol. 2020;21:612-614.
   PubMed    
   
   
   April 2020
6. BATTISTI NML, Ring A
   CDK4/6 inhibition in HER2-positive breast cancer.
   Lancet Oncol. 2020 Apr 27. pii: S1470-2045(20)30164.
   PubMed    
   
   
   
7. TOLANEY SM, Wardley AM, Zambelli S, Hilton JF, et al
   Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
   Lancet Oncol. 2020 Apr 27. pii: S1470-2045(20)30112.
   PubMed     Abstract available
   
   
   
8. THOMPSON AM
   Breast conservation therapy versus mastectomy for breast cancer.
   Lancet Oncol. 2020;21:493-494.
   PubMed    
   
   
   
9. ROYCE TJ, Gupta GP, Marks LB
   Breast conservation therapy versus mastectomy for breast cancer.
   Lancet Oncol. 2020;21:492-493.
   PubMed    
   
   
   March 2020
10. LAMBERTINI M, Vaz-Luis I
    Is HER2-positive metastatic breast cancer still an incurable disease?
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(20)30058.
    PubMed    
    
    
    
11. SWAIN SM, Miles D, Kim SB, Im YH, et al
    Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Lancet Oncol. 2020 Mar 12. pii: S1470-2045(19)30863.
    PubMed     Abstract available
    
    
    
12. STIRRUPS R
    Pembrolizumab for triple-negative breast cancer.
    Lancet Oncol. 2020 Mar 5. pii: S1470-2045(20)30154.
    PubMed    
    
    
    
13. GAO JJ, Cheng J, Beaver JA, Prowell TM, et al
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy - Authors' reply.
    Lancet Oncol. 2020;21:e131.
    PubMed    
    
    
    
14. PALA L, Conforti F, Goldhirsch A
    Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy.
    Lancet Oncol. 2020;21:e130.
    PubMed    
    
    
    
15. COLEMAN R, Zhou Y, Chan A
    Adjuvant denosumab in early breast cancer - Authors' reply.
    Lancet Oncol. 2020;21:e125.
    PubMed    
    
    
    
16. FUSCO V, Campisi G, Bedogni A
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e124.
    PubMed    
    
    
    
17. DE BOISSIEU P, Trenque T
    Adjuvant denosumab in early breast-cancer.
    Lancet Oncol. 2020;21:e123.
    PubMed    
    
    
    
18. SCIMECA M, Bonfiglio R, Urbano N, Schillaci O, et al
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e122.
    PubMed    
    
    
    
19. PETERS N, Conroy M, O'Reilly S
    Adjuvant denosumab in early breast cancer.
    Lancet Oncol. 2020;21:e121.
    PubMed    
    
    
    February 2020
20. JONES RH, Casbard A, Carucci M, Cox C, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30817.
    PubMed     Abstract available
    
    
    
21. NASRAZADANI A, Brufsky AM
    Capivasertib inhibits a key pathway in metastatic breast cancer.
    Lancet Oncol. 2020 Feb 5. pii: S1470-2045(19)30857.
    PubMed    
    
    
    January 2020
22. NUZZOLESE I, Montemurro F
    Attrition in metastatic breast cancer: a metric to be reported in randomised clinical trials?
    Lancet Oncol. 2020;21:21-24.
    PubMed    
    
    
    December 2019
23. GOURD K
    San Antonio Breast Cancer Symposium 2019.
    Lancet Oncol. 2019 Dec 19. pii: S1470-2045(19)30830.
    PubMed    
    
    
    
24. CURIGLIANO G, Loibl S
    CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30808.
    PubMed    
    
    
    
25. GAO JJ, Cheng J, Bloomquist E, Sanchez J, et al
    CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30804.
    PubMed     Abstract available
    
    
    
26. CRISTOFANILLI M
    Time for a shift in molecular down staging in luminal breast cancer.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30806.
    PubMed    
    
    
    
27. PRAT A, Saura C, Pascual T, Hernando C, et al
    Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2019 Dec 11. pii: S1470-2045(19)30786.
    PubMed     Abstract available
    
    
    
28. COLEMAN R, Finkelstein DM, Barrios C, Martin M, et al
    Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
    Lancet Oncol. 2019 Dec 2. pii: S1470-2045(19)30687.
    PubMed     Abstract available
    
    
    
29. PERRONE F, Gravina A
    Denosumab in early breast cancer: negative data and a call to action.
    Lancet Oncol. 2019 Dec 2. pii: S1470-2045(19)30717.
    PubMed    
    
    
    November 2019
30. WOODWARD WA
    Building momentum for subsets of patients with advanced triple-negative breast cancer.
    Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30737.
    PubMed    
    
    
    
31. SCHMID P, Rugo HS, Adams S, Schneeweiss A, et al
    Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30689.
    PubMed     Abstract available
    
    
    October 2019
32. PARK YH, Kim TY, Kim GM, Kang SY, et al
    Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 tr
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30565.
    PubMed     Abstract available
    
    
    
33. DAS M
    Promising radiotherapy classifier for early breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30720.
    PubMed    
    
    
    
34. ROBERT M, Turner N
    Endocrine-based therapy versus chemotherapy in advanced breast cancer.
    Lancet Oncol. 2019 Oct 24. pii: S1470-2045(19)30686.
    PubMed    
    
    
    
35. STIRRUPS R
    Abemaciclib plus fulvestrant for breast cancer.
    Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30629.
    PubMed    
    
    
    September 2019
36. GOEL S, Tolaney SM
    CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30627.
    PubMed    
    
    
    
37. TAN AR, Wright GS, Thummala AR, Danso MA, et al
    Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Lancet Oncol. 2019 Sep 27. pii: S1470-2045(19)30616.
    PubMed     Abstract available
    
    
    
38. GIULIANO M, Schettini F, Rognoni C, Milani M, et al
    Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Lancet Oncol. 2019 Sep 4. pii: S1470-2045(19)30420.
    PubMed     Abstract available
    
    
    
39. NAROD SA
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc).
    Lancet Oncol. 2019;20:e465.
    PubMed    
    
    
    
40. ZOLNIKOV TR, Chambers D
    Barriers to treatment for patients with breast cancer in Kenya.
    Lancet Oncol. 2019;20:1206-1207.
    PubMed    
    
    
    August 2019
41. GOURD E
    Pyrotinib versus lapatinib in HER2-positive breast cancer.
    Lancet Oncol. 2019 Aug 30. pii: S1470-2045(19)30568.
    PubMed    
    
    
    
42. JACKISCH C
    Overcoming endocrine resistance in neoadjuvant endocrine therapy for early breast cancer.
    Lancet Oncol. 2019 Aug 8. pii: S1470-2045(19)30500.
    PubMed    
    
    
    
43. SAURA C, Hlauschek D, Oliveira M, Zardavas D, et al
    Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Lancet Oncol. 2019 Aug 8. pii: S1470-2045(19)30334.
    PubMed     Abstract available
    
    
    June 2019
44. BANERJI U, van Herpen CML, Saura C, Thistlethwaite F, et al
    Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
    Lancet Oncol. 2019 Jun 27. pii: S1470-2045(19)30328.
    PubMed     Abstract available
    
    
    
45. SAADATMAND S, Geuzinge HA, Rutgers EJT, Mann RM, et al
    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30275.
    PubMed     Abstract available
    
    
    
46. KUHL CK
    Underdiagnosis is the main challenge in breast cancer screening.
    Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30314.
    PubMed    
    
    
    
47. BURKI TK
    Night shift work and breast cancer.
    Lancet Oncol. 2019 Jun 6. pii: S1470-2045(19)30383.
    PubMed    
    
    
    
48. TERRY MB, Liao Y, Hopper JL, MacInnis RJ, et al
    Performance of BCRAT in high-risk patients with breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:e286.
    PubMed    
    
    
    
49. GAIL MH
    Performance of BCRAT in high-risk patients with breast cancer.
    Lancet Oncol. 2019;20:e285.
    PubMed    
    
    
    May 2019
50. STIRRUPS R
    Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30372.
    PubMed    
    
    
    
51. DAS M
    GM1 for taxane-induced neuropathy in breast cancer.
    Lancet Oncol. 2019 May 23. pii: S1470-2045(19)30373.
    PubMed    
    
    
    
52. VARATHARAJAH R
    Breast cancer screening by visually impaired women.
    Lancet Oncol. 2019 May 10. pii: S1470-2045(19)30290.
    PubMed    
    
    
    
53. HOFVIND S, Holen AS, Aase HS, Houssami N, et al
    Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial.
    Lancet Oncol. 2019 May 8. pii: S1470-2045(19)30161.
    PubMed     Abstract available
    
    
    
54. BRANDAO M, Debiasi M, de Azambuja E
    Denosumab in early-stage breast cancer.
    Lancet Oncol. 2019;20:e234-e235.
    PubMed    
    
    
    
55. RODRIGUEZ EG, Aubry-Rozier B, Stoll D, Lamy O, et al
    Denosumab in early-stage breast cancer.
    Lancet Oncol. 2019;20:e233.
    PubMed    
    
    
    
56. GNANT M, Pfeiler G, Frantal S
    Denosumab in early-stage breast cancer - Authors' reply.
    Lancet Oncol. 2019;20:236.
    PubMed    
    
    
    April 2019
57. TAMURA K, Tsurutani J, Takahashi S, Iwata H, et al
    Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Lancet Oncol. 2019 Apr 29. pii: S1470-2045(19)30097.
    PubMed     Abstract available
    
    
    
58. WANDER SA, Spring LM, Bardia A
    Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30279.
    PubMed    
    
    
    
59. JIANG Z, Li W, Hu X, Zhang Q, et al
    Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Apr 26. pii: S1470-2045(19)30164.
    PubMed     Abstract available
    
    
    
60. BURKI TK
    Fulvestrant plus anastrozole for metastatic breast cancer.
    Lancet Oncol. 2019 Apr 4. pii: S1470-2045(19)30217.
    PubMed    
    
    
    March 2019
61. DAS M
    Supplemental ultrasonography for breast cancer screening.
    Lancet Oncol. 2019 Mar 28. pii: S1470-2045(19)30211.
    PubMed    
    
    
    
62. STIRRUPS R
    Neratinib and capecitabine for breast cancer brain metastases.
    Lancet Oncol. 2019 Mar 22. pii: S1470-2045(19)30184.
    PubMed    
    
    
    
63. CHAE SY, Ahn SH, Kim SB, Han S, et al
    Diagnostic accuracy and safety of 16alpha-[(18)F]fluoro-17beta-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.
    Lancet Oncol. 2019 Mar 4. pii: S1470-2045(18)30936.
    PubMed     Abstract available
    
    
    
64. MANKOFF DA, Clark AS
    PET oestrogen receptor imaging: ready for the clinic?
    Lancet Oncol. 2019 Mar 4. pii: S1470-2045(19)30038.
    PubMed    
    
    
    
65. ESTEVA FJ, Hubbard-Lucey VM, Tang J, Pusztai L, et al
    Immunotherapy and targeted therapy combinations in metastatic breast cancer.
    Lancet Oncol. 2019;20:e175-e186.
    PubMed     Abstract available
    
    
    
66. CATANIA G, Ghirotto L, Leo SD, Timmins F, et al
    What a picture can tell you about surviving breast cancer.
    Lancet Oncol. 2019;20:335.
    PubMed    
    
    
    February 2019
67. STIRRUPS R
    Sacituzumab govitecan-hziy for triple-negative breast cancer.
    Lancet Oncol. 2019 Feb 28. pii: S1470-2045(19)30074.
    PubMed    
    
    
    
68. TERRY MB, Liao Y, Whittemore AS, Leoce N, et al
    10-year performance of four models of breast cancer risk: a validation study.
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(18)30902.
    PubMed     Abstract available
    
    
    
69. GARCIA-CLOSAS M, Chatterjee N
    Assessment of breast cancer risk: which tools to use?
    Lancet Oncol. 2019 Feb 21. pii: S1470-2045(19)30071.
    PubMed    
    
    
    
70. GNANT M, Pfeiler G, Steger GG, Egle D, et al
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30862.
    PubMed     Abstract available
    
    
    
71. LIPPMAN M
    Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Lancet Oncol. 2019 Feb 19. pii: S1470-2045(18)30913.
    PubMed    
    
    
    
72. PEOPLES GE
    Improving the outcomes of checkpoint inhibitors in breast cancer.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(19)30068.
    PubMed    
    
    
    
73. LOI S, Giobbie-Hurder A, Gombos A, Bachelot T, et al
    Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Lancet Oncol. 2019 Feb 11. pii: S1470-2045(18)30812.
    PubMed     Abstract available
    
    
    January 2019
74. WANG SL, Fang H, Song YW, Wang WH, et al
    Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Lancet Oncol. 2019 Jan 30. pii: S1470-2045(18)30813.
    PubMed     Abstract available
    
    
    
75. SAAD ED, Squifflet P, Burzykowski T, Quinaux E, et al
    Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30750.
    PubMed     Abstract available
    
    
    
76. AMIR E
    Endpoint selection in HER2-positive early breast cancer.
    Lancet Oncol. 2019 Jan 29. pii: S1470-2045(18)30779.
    PubMed    
    
    
    
77. GOURD E
    Degarelix improves suppression of ovarian function.
    Lancet Oncol. 2019 Jan 11. pii: S1470-2045(19)30001.
    PubMed    
    
    
    December 2018
78. BURKI TK
    T-DM1 for residual, invasive, HER2-positive breast cancer.
    Lancet Oncol. 2018 Dec 13. pii: S1470-2045(18)30918.
    PubMed    
    
    
    November 2018
79. VAN RAMSHORST MS, van der Voort A, van Werkhoven ED, Mandjes IA, et al
    Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    Lancet Oncol. 2018 Nov 6. pii: S1470-2045(18)30570.
    PubMed     Abstract available
    
    
    October 2018
80. VELIKOVA G, Williams LJ, Willis S, Dixon JM, et al
    Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
    Lancet Oncol. 2018 Oct 15. pii: S1470-2045(18)30515.
    PubMed     Abstract available
    
    
    
81. YAFFE MJ
    Towards improving accuracy, effectiveness, and efficiency in breast cancer screening.
    Lancet Oncol. 2018 Oct 12. pii: S1470-2045(18)30589.
    PubMed    
    
    
    September 2018
82. GOURD E
    Lurbinectedin for BRCA-mutated advanced breast cancer.
    Lancet Oncol. 2018 Sep 27. pii: S1470-2045(18)30737.
    PubMed    
    
    
    
83. STIRRUPS R
    Atezolizumab for metastatic triple-negative breast cancer.
    Lancet Oncol. 2018 Sep 20. pii: S1470-2045(18)30706.
    PubMed    
    
    
    
84. KUERER HM
    More evidence for further minimisation of breast-cancer surgery.
    Lancet Oncol. 2018 Sep 5. pii: S1470-2045(18)30416.
    PubMed    
    
    
    
85. GALIMBERTI V, Cole BF, Viale G, Veronesi P, et al
    Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
    Lancet Oncol. 2018 Sep 5. pii: S1470-2045(18)30380.
    PubMed     Abstract available
    
    
    
86. PE M, Dorme L, Coens C, Basch E, et al
    Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.
    Lancet Oncol. 2018;19:e459-e469.
    PubMed     Abstract available
    
    
    August 2018
87. GUNJUR A
    Talazoparib for BRCA-mutated advanced breast cancer.
    Lancet Oncol. 2018 Aug 23. pii: S1470-2045(18)30650.
    PubMed    
    
    
    
88. GOURD E
    New triple-negative breast cancer risk genes identified.
    Lancet Oncol. 2018 Aug 16. pii: S1470-2045(18)30614.
    PubMed    
    
    
    
89. DERLIN T, Hueper K
    CXCR4-targeted therapy in breast cancer.
    Lancet Oncol. 2018;19:e370.
    PubMed    
    
    
    
90. NICHOLLS E
    Breast cancer in a Renaissance Book of the Dead.
    Lancet Oncol. 2018;19:1023-1024.
    PubMed    
    
    
    
91. GOURD E
    Mammography deficiencies: the result of poor positioning.
    Lancet Oncol. 2018;19:e385.
    PubMed    
    
    
    July 2018
92. MARTIN M
    The LILAC trial and the blooming of anticancer biosimilars.
    Lancet Oncol. 2018;19:861-863.
    PubMed    
    
    
    June 2018
93. BURKI TK
    Variations in breast cancer treatment and outcomes.
    Lancet Oncol. 2018 Jun 14. pii: S1470-2045(18)30451.
    PubMed    
    
    
    
94. VON MINCKWITZ G, Colleoni M, Kolberg HC, Morales S, et al
    Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    Lancet Oncol. 2018 Jun 4. pii: S1470-2045(18)30241.
    PubMed     Abstract available
    
    
    May 2018
95. MURTHY R, Borges VF, Conlin A, Chaves J, et al
    Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30256.
    PubMed     Abstract available
    
    
    
96. FOUKAKIS T
    Ribociclib in premenopausal women with advanced breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30367.
    PubMed    
    
    
    
97. TRIPATHY D, Im SA, Colleoni M, Franke F, et al
    Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30292.
    PubMed     Abstract available
    
    
    
98. BURKI TK
    Responses to carboplatin in BRCA1/2-mutated breast cancer.
    Lancet Oncol. 2018 May 24. pii: S1470-2045(18)30407.
    PubMed    
    
    
    
99. GOURD E
    Low uptake of tamoxifen to prevent breast cancer.
    Lancet Oncol. 2018 May 3. pii: S1470-2045(18)30344.
    PubMed    
    
    
    April 2018
100. PERNAS S, Martin M, Kaufman PA, Gil-Martin M, et al
     Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
     Lancet Oncol. 2018 Apr 26. pii: S1470-2045(18)30147.
     PubMed     Abstract available
     
     
     
101. SCHAFER R, Strnad V, Polgar C, Uter W, et al
     Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
     Lancet Oncol. 2018 Apr 20. pii: S1470-2045(18)30195.
     PubMed     Abstract available
     
     
     
102. ECCLES DM, Copson ER
     Genetic testing for young women with breast cancer - Authors' reply.
     Lancet Oncol. 2018;19:e183.
     PubMed    
     
     
     
103. METCALFE K, Akbari MR, Narod SA
     Genetic testing for young women with breast cancer.
     Lancet Oncol. 2018;19:e182.
     PubMed    
     
     
     March 2018
104. MCGALE P, Dodwell D, Taylor C, Gray R, et al
     Neoadjuvant chemotherapy for early breast cancer - Author's reply.
     Lancet Oncol. 2018;19:e130.
     PubMed    
     
     
     
105. KRUG D, Loibl S
     Neoadjuvant chemotherapy for early breast cancer.
     Lancet Oncol. 2018;19:e129.
     PubMed    
     
     
     
106. CHARALAMPOUDIS P, Karakatsanis A
     Neoadjuvant chemotherapy for early breast cancer.
     Lancet Oncol. 2018;19:e128.
     PubMed    
     
     
     February 2018
107. CURIGLIANO G
     Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
     Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30129.
     PubMed    
     
     
     
108. LOIBL S, O'Shaughnessy J, Untch M, Sikov WM, et al
     Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
     Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111.
     PubMed     Abstract available
     
     
     
109. DE PLACIDO S, Gallo C, De Laurentiis M, Bisagni G, et al
     Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
     Lancet Oncol. 2018 Feb 23. pii: S1470-2045(18)30116.
     PubMed     Abstract available
     
     
     
110. WILDIERS H, Tryfonidis K, Dal Lago L, Vuylsteke P, et al
     Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
     Lancet Oncol. 2018 Feb 9. pii: S1470-2045(18)30083.
     PubMed     Abstract available
     
     
     
111. BIANUCCI R, Perciaccante A, Charlier P, Appenzeller O, et al
     Earliest evidence of malignant breast cancer in Renaissance paintings.
     Lancet Oncol. 2018;19:166-167.
     PubMed    
     
     
     January 2018
112. FASCHING PA
     Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
     Lancet Oncol. 2018 Jan 11. pii: S1470-2045(18)30008.
     PubMed    
     
     
     
113. COPSON ER, Maishman TC, Tapper WJ, Cutress RI, et al
     Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
     Lancet Oncol. 2018 Jan 11. pii: S1470-2045(17)30891.
     PubMed     Abstract available
     
     
     
114. GIANNI L, Bisagni G, Colleoni M, Del Mastro L, et al
     Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
     Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30001.
     PubMed     Abstract available
     
     
     
115. PIVOT X, Cox DG
     A new era for treatment development in HER2-positive breast cancer.
     Lancet Oncol. 2018 Jan 8. pii: S1470-2045(18)30002.
     PubMed    
     
     
     
116. MALAGA G, Cuba-Fuentes S, Romero-Albino Z
     Implementation of a community-based breast cancer management programme.
     Lancet Oncol. 2018;19:e3.
     PubMed    
     
     
     
117. GLIGOROV J
     Early HER2-positive breast cancers: time for a new revolution?
     Lancet Oncol. 2018;19:12-13.
     PubMed    
     
     
     
118. CHLEBOWSKI RT, Pan K
     Complexity of intermittent letrozole adjuvant therapy.
     Lancet Oncol. 2018;19:13-15.
     PubMed    
     
     
     December 2017
119. BURKI TK
     Improved progression-free survival in metastatic breast cancer.
     Lancet Oncol. 2017 Dec 21. pii: S1470-2045(17)30952.
     PubMed    
     
     
     
120. NELSON R
     San Antonio Breast Cancer Symposium 2017.
     Lancet Oncol. 2017 Dec 14. pii: S1470-2045(17)30930.
     PubMed    
     
     
     
121. DERKS MGM, van de Velde CJH
     Neoadjuvant chemotherapy in breast cancer: more than just downsizing.
     Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30914.
     PubMed    
     
     
     
122. 
     Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
     Lancet Oncol. 2017 Dec 11. pii: S1470-2045(17)30777.
     PubMed     Abstract available
     
     
     
123. SALGADO R, Loi S
     Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance.
     Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30905.
     PubMed    
     
     
     
124. DENKERT C, von Minckwitz G, Darb-Esfahani S, Lederer B, et al
     Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
     Lancet Oncol. 2017 Dec 7. pii: S1470-2045(17)30904.
     PubMed     Abstract available
     
     
     
125. DI LEO A, Johnston S, Lee KS, Ciruelos E, et al
     Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
     Lancet Oncol. 2017 Dec 6. pii: S1470-2045(17)30688.
     PubMed     Abstract available
     
     
     
126. HO AY, Hu ZI, Mehrara BJ, Wilkins EG, et al
     Radiotherapy in the setting of breast reconstruction: types, techniques, and timing.
     Lancet Oncol. 2017;18:e742-e753.
     PubMed     Abstract available
     
     
     November 2017
127. HURVITZ SA, Martin M, Symmans WF, Jung KH, et al
     Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
     Lancet Oncol. 2017 Nov 23. pii: S1470-2045(17)30716.
     PubMed     Abstract available
     
     
     
128. COLLEONI M, Luo W, Karlsson P, Chirgwin J, et al
     Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
     Lancet Oncol. 2017 Nov 17. pii: S1470-2045(17)30715.
     PubMed     Abstract available
     
     
     
129. MARTIN M, Holmes FA, Ejlertsen B, Delaloge S, et al
     Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
     Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30717.
     PubMed     Abstract available
     
     
     
130. CHAVEZ-MACGREGOR M, Mittendorf EA
     Extended adjuvant therapy in patients with HER2-positive breast cancer: some answers, even more questions.
     Lancet Oncol. 2017 Nov 13. pii: S1470-2045(17)30844.
     PubMed    
     
     
     
131. GOURD E
     Thermography should not be used in breast cancer screening.
     Lancet Oncol. 2017 Nov 2. pii: S1470-2045(17)30833.
     PubMed    
     
     
     October 2017
132. COSTA L, Ferreira AR
     Adjuvant zoledronic acid to treat breast cancer: not for all.
     Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30695.
     PubMed    
     
     
     
133. COLEMAN R, Hall A, Albanell J, Hanby A, et al
     Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
     Lancet Oncol. 2017 Oct 13. pii: S1470-2045(17)30603.
     PubMed     Abstract available
     
     
     
134. GOURD E
     Insulin analog linked to breast cancer risk.
     Lancet Oncol. 2017 Oct 5. pii: S1470-2045(17)30772.
     PubMed    
     
     
     
135. DUGGAN C, Dvaladze AL, Tsu V, Jeronimo J, et al
     Resource-stratified implementation of a community-based breast cancer management programme in Peru.
     Lancet Oncol. 2017;18:e607-e617.
     PubMed     Abstract available
     
     
     
136. PINEROS M, Ramos W, Antoni S, Abriata G, et al
     Cancer patterns, trends, and transitions in Peru: a regional perspective.
     Lancet Oncol. 2017;18:e573-e586.
     PubMed     Abstract available
     
     
     September 2017
137. GOURD E
     Pyrotinib shows activity in metastatic breast cancer.
     Lancet Oncol. 2017 Sep 21. pii: S1470-2045(17)30755.
     PubMed    
     
     
     August 2017
138. KERR J, Anderson C, Lippman SM
     Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.
     Lancet Oncol. 2017;18:e457-e471.
     PubMed     Abstract available
     
     
     
139. LEVIS BE, Binkley PF, Shapiro CL
     Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
     Lancet Oncol. 2017;18:e445-e456.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: